CJC-1295 & Ipamorelin Research

Overview

CJC-1295 and Ipamorelin are two of the most widely studied growth hormone secretagogue (GHS) peptides in preclinical research. While they operate through different receptor pathways, they are frequently studied together due to their complementary mechanisms — CJC-1295 acts on the GHRH receptor, while Ipamorelin targets the ghrelin receptor.

CJC-1295: GHRH Analogue

Structure & Mechanism

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH), consisting of 29 amino acids. It binds to the GHRH receptor on anterior pituitary somatotroph cells, stimulating the synthesis and release of growth hormone (GH). Unlike native GHRH, which has a plasma half-life of approximately 7 minutes, CJC-1295 has been engineered for extended stability.

DAC vs. No-DAC Variants

CJC-1295 exists in two research variants:

• CJC-1295 with DAC (Drug Affinity Complex): The DAC modification enables binding to serum albumin, extending the effective half-life to approximately 6-8 days. This variant produces sustained, elevated GH levels over an extended period.
• CJC-1295 without DAC (Modified GRF 1-29): Shorter half-life (approximately 30 minutes), producing pulsatile GH release that more closely mimics physiological GH secretion patterns. Often preferred in research studying natural GH pulsatility.

Key Research Findings

Published studies have demonstrated that CJC-1295 administration in animal models produces dose-dependent increases in plasma GH and IGF-1 levels. Research by Teichman et al. (2006) showed sustained elevation of GH levels following CJC-1295 (DAC) administration, with effects persisting for days rather than hours.

Ipamorelin: Selective GHS Receptor Agonist

Structure & Mechanism

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective growth hormone secretagogue receptor (GHS-R) agonist — the same receptor targeted by ghrelin. Unlike other GHS-R agonists such as GHRP-6, Ipamorelin demonstrates high selectivity for GH release without significantly affecting cortisol, prolactin, or ACTH levels in preclinical studies.

Selectivity Advantage

The selectivity of Ipamorelin is a key differentiator in research contexts. Studies by Raun et al. (1998) demonstrated that Ipamorelin stimulates GH release with potency comparable to GHRP-6, but with minimal effects on other pituitary hormones. This selectivity makes it a valuable research tool for studying isolated GH axis modulation.

Synergistic Research

CJC-1295 and Ipamorelin are frequently studied in combination because they act through complementary mechanisms:

• CJC-1295 stimulates GH synthesis and release via the GHRH receptor (amplifying the "supply")
• Ipamorelin triggers GH pulse release via the ghrelin receptor (amplifying the "signal")

Research suggests that combining GHRH analogues with GHS-R agonists produces synergistic — not merely additive — GH release. This makes the CJC-1295/Ipamorelin combination a popular research model for studying GH axis amplification.

Handling & Storage

• Lyophilised storage: -20°C for long-term, 2-8°C for short-term
• Reconstitution: Bacteriostatic water or sterile water. Add slowly along vial wall, swirl gently.
• Post-reconstitution: Store at 2-8°C. Use within 21 days (BAC water) or 48 hours (sterile water).
• Light sensitivity: Moderate. Store away from direct light.